Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129856 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye
A Phase 3 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 198
- Enrollment target
NCT01129856 is a Phase 3 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 198 participants.
The verdict
NCT01129856, a Phase 3 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 198 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.
Interventions
- DRUG Dexamethasone phosphate ophthalmic solution
- DRUG Sodium citrate buffer solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129856
The ClinicalTrials.gov registry entry for NCT01129856 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyegate Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone phosphate ophthalmic solution is the first listed.
NCT01129856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129856 about?
NCT01129856 is a clinical study titled "Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye". The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.
What is the current status of trial NCT01129856?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 198 participants. The study started on 2010-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01129856?
The interventions under investigation include: Dexamethasone phosphate ophthalmic solution (DRUG), Sodium citrate buffer solution (DRUG).
Who is sponsoring clinical trial NCT01129856?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.